(toipiramate, Ortho-McNeil Pharmaceutical Inc.)
An anticonvulsant for add-on therapy in people aged 2 and older with seizures related to Lennox-Gastaut syndrome. Previously approved as adjunctive therapy for partial-onset seizures and primary generalized tonic-clonic seizures.
* Dosage: 400 mg a day in two divided doses (for age 17 and over).
Most Popular
10 Jobs That P…
Most Popular
13 Job Interview Mistakes To Avoid
3 Questions No Job Seeker Ever Wants To Be Asked?
Public Speaking: 7 Secrets Of Great Public Speakers
10 Jobs That Pay $30 An Hour
Request Fo…
BRECKENRIDGE, COLO. — Topiramate monotherapy at a target dosage of 100 mg/day–substantially less than conventional dosing–is at least as effective as standard therapeutic doses of carbamazepine or valproate for newly diagnosed epilepsy regardless of seizure type, Jacci Bainbridge, Pharm.D., said at a conference on epilepsy syndromes sponsored by the University of Texas at San Antonio.
…
ATHENS, Greece, September 19 /PRNewswire/ — Results from two large clinical trials demonstrate that patients with frequent migraine who were treated with TOPAMAX(R) (topiramate) for up to 14 months (6 months double blind followed by 8 months open label) had a persistent reduction in the frequency of migraine headaches(1).
Related Results
…
Sponsored by Corbett Accel Healthcare Group
GOLD AWARD
Conetics and Ortho-McNeil Neurologies for Topamax Migraine
2007 Media Plan for Topamax Migraine
Judges awarded the Gold for Ortho-McNeil Neurologies’ Topmax campaign’s segmentation strategy, calling it a “nicely executed, well thought-out segmentation analysis.”
Topamax is a widely prescribed migraine preventative, boasting strong sales…
TITUSVILLE, N.J., July 24 /PRNewswire/ — Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for TOPAMAX(R) (topiramate), based on studies submitted in response to a Written Request by the FDA to investigate the use of TOPAMAX in pediatric patients aged 1 to 24 months with partial onset seizures.
In addition to granting pediatric exclusivi…
(Full text of statement. Contact details below.)
LONDON, Sept 23 PRNewswire Asia-AsiaNet — A new study presented today at the 14th Migraine Trust International Symposium shows that topiramate,…
(topiramate, Ortho-McNeil Pharmaceutical Inc.)
An anticonvulsant for add-on therapy in people aged 2 and older with seizures related to Lennox-Gastaut syndrome, the third anticonvulsant approved for this devastating form of epilepsy Previously approved as adjunctive therapy for partial-onset seizures and primary, generalized tonic-clonic seizures in children and adults.
Dosage…
WASHINGTON INSIDER
Related Results
…
